Detalles de la búsqueda
1.
Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial.
J Headache Pain
; 25(1): 43, 2024 Mar 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-38528476
2.
Phase 2 randomized placebo-controlled study of lasmiditan for the acute treatment of migraine in Japanese patients.
Headache
; 61(5): 755-765, 2021 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-33990951
3.
Clinical Evaluation After Discontinuation of Galcanezumab in Japanese Patients with Episodic and Chronic Migraine: Analysis of a Randomized, Placebo-Controlled Trial and Open-label Extension Study.
Neurol Ther
; 13(3): 697-714, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38581615
4.
Safety profile of lasmiditan in patients with migraine in an Asian population.
Expert Opin Drug Saf
; 22(1): 91-101, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-35736027
5.
Galcanezumab Efficacy Through the Dosing Interval in Japanese Patients with Episodic Migraine: Post Hoc Analysis of a Phase 2 Randomized Trial.
Neurol Ther
; 12(6): 2007-2019, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37698836
6.
Lasmiditan in Japanese Patients with Common Migraine Comorbidities or Concomitant Medications: A Post Hoc Safety and Efficacy Analysis from the MONONOFU Study.
J Pain Res
; 16: 1725-1738, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37255987
7.
Lasmiditan for single migraine attack in Japanese patients with cardiovascular risk factors: subgroup analysis of a phase 2 randomized placebo-controlled trial.
Expert Opin Drug Saf
; 21(12): 1495-1503, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-35748397
8.
Efficacy of Lasmiditan Across Patient and Migraine Characteristics in Japanese Patients with Migraine: A Secondary Analysis of the MONONOFU Trial.
Adv Ther
; 39(11): 5274-5288, 2022 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-36138260
9.
Rapid Onset and Sustained Efficacy of Lasmiditan Among Japanese Patients with Migraine: Prespecified Analyses of a Randomized Controlled Trial.
Neurol Ther
; 11(4): 1721-1734, 2022 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-36136232
10.
Safety and effectiveness of rapid-acting intra-muscular olanzapine for agitation associated with schizophrenia - Japan postmarketing surveillance study.
Neuropsychiatr Dis Treat
; 14: 265-272, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29391799
11.
Effectiveness and safety of oral olanzapine treatment transitioned from rapid-acting intramuscular olanzapine for agitation associated with schizophrenia.
Neuropsychiatr Dis Treat
; 14: 1083-1091, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29719399
12.
Perceptions and impact of bipolar disorder in Japan: results of an Internet survey.
Neuropsychiatr Dis Treat
; 12: 2981-2987, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27920534
13.
Effectiveness of Simple Individual Psychoeducation for Bipolar II Disorder.
Case Rep Psychiatry
; 2016: 6062801, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27559486
14.
Predictors of antipsychotic monotherapy with olanzapine during a 1-year naturalistic study of schizophrenia patients in Japan.
Clinicoecon Outcomes Res
; 4: 13-9, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22347801
15.
Antipsychotic monotherapy among outpatients with schizophrenia treated with olanzapine or risperidone in Japan: a health care database analysis.
Neuropsychiatr Dis Treat
; 8: 259-66, 2012.
Artículo
en Inglés
| MEDLINE | ID: mdl-22745559
16.
Predictors of continuation with olanzapine during the 1-year naturalistic treatment of patients with schizophrenia in Japan.
Patient Prefer Adherence
; 5: 611-7, 2011.
Artículo
en Inglés
| MEDLINE | ID: mdl-22259238
Resultados
1 -
16
de 16
1
Próxima >
>>